Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Amy C, Burke"'
Autor:
Nadya M. Morrow, Amy C. Burke, Joshua P. Samsoondar, Kyle E. Seigel, Andrew Wang, Dawn E. Telford, Brian G. Sutherland, Conor O'Dwyer, Gregory R. Steinberg, Morgan D. Fullerton, Murray W. Huff
Publikováno v:
Journal of Lipid Research, Vol 61, Iss 3, Pp 387-402 (2020)
Obesity, dyslipidemia, and insulin resistance, the increasingly common metabolic syndrome, are risk factors for CVD and type 2 diabetes that warrant novel therapeutic interventions. The flavonoid nobiletin displays potent lipid-lowering and insulin-s
Externí odkaz:
https://doaj.org/article/4cda3eb4c2104e2fabdf5d55dfd633bf
Autor:
Amy C. Burke, Brian G. Sutherland, Dawn E. Telford, Marisa R. Morrow, Cynthia G. Sawyez, Jane Y. Edwards, Maria Drangova, Murray W. Huff
Publikováno v:
Journal of Lipid Research, Vol 59, Iss 9, Pp 1714-1728 (2018)
Obesity and its associated metabolic dysfunction and cardiovascular disease risk represent a leading cause of adult morbidity worldwide. Currently available pharmacological therapies for obesity have had limited success in reversing existing obesity
Externí odkaz:
https://doaj.org/article/761ce2d5872b400187ff5a277fcec253
Autor:
Murray W. Huff, Nadya M. Morrow, Conor O’Dwyer, Andrew Wang, Gregory R. Steinberg, Morgan D. Fullerton, Joshua P. Samsoondar, Kyle E. Seigel, Amy C. Burke, Dawn E. Telford, Brian G. Sutherland
Publikováno v:
Journal of Lipid Research, Vol 61, Iss 3, Pp 387-402 (2020)
J Lipid Res
J Lipid Res
Obesity, dyslipidemia, and insulin resistance, the increasingly common metabolic syndrome, are risk factors for CVD and type 2 diabetes that warrant novel therapeutic interventions. The flavonoid nobiletin displays potent lipid-lowering and insulin-s
Publikováno v:
British Journal of Learning Disabilities. 47:255-263
Publikováno v:
Current Opinion in Lipidology. 30:1-9
Bempedoic acid has emerged as a potent inhibitor of ATP-citrate lyase (ACLY), a target for the reduction of LDL cholesterol (LDL-C). We review the impact of bempedoic acid treatment on lipoprotein metabolism and atherosclerosis in preclinical models
Publikováno v:
Sexualities. :136346072210881
In this article, the authors explore the place-based experiences of sex workers and how these experiences intersect with the juridical realm of sex work. The article begins with an overview of the model informing Canadian legislation, how these laws
Autor:
Marisa R. Morrow, Brian G. Sutherland, Jane Y. Edwards, Dawn E. Telford, Amy C. Burke, Maria Drangova, Cynthia G. Sawyez, Murray W. Huff
Publikováno v:
Journal of Lipid Research, Vol 59, Iss 9, Pp 1714-1728 (2018)
Medical Biophysics Publications
Bone and Joint Institute
Medical Biophysics Publications
Bone and Joint Institute
Copyright © 2018 Burke et al. Obesity and its associated metabolic dysfunction and cardiovascular disease risk represent a leading cause of adult morbidity worldwide. Currently available pharmacological therapies for obesity have had limited success
Autor:
Jane Y. Edwards, J. Geoffrey Pickering, Brian G. Sutherland, Cynthia G. Sawyez, Amy C. Burke, Murray W. Huff, Dawn E. Telford, P. Hugh R. Barrett, Roger S. Newton
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 38:1178-1190
Objective— Bempedoic acid (BemA; ETC-1002) is a novel drug that targets hepatic ATP-citrate lyase to reduce cholesterol biosynthesis. In phase 2 studies, BemA lowers elevated low-density lipoprotein cholesterol (LDL-C) in hypercholesterolemic patie
Autor:
Dawn E. Telford, Cynthia G. Sawyez, Roger S. Newton, Amy C. Burke, Murray W. Huff, Stephen L. Pinkosky, Jane Y. Edwards, Joshua P. Samsoondar, Brian G. Sutherland
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 37:647-656
Objective— Bempedoic acid (ETC-1002, 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid) is a novel low-density lipoprotein cholesterol–lowering compound. In animals, bempedoic acid targets the liver where it inhibits cholesterol and fatty acid
Autor:
Murray W. Huff, Amy C. Burke
Publikováno v:
Current opinion in lipidology. 29(2)
Regression, or reversal, of atherosclerosis has become an important clinical objective. The development of consistent models of murine atherosclerosis regression has accelerated this field of research. The purpose of this review is to highlight recen